{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:46:46Z","timestamp":1782506806799,"version":"3.54.5"},"reference-count":20,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To compare the clinical efficacy of the curved vertebroplasty system combined with targeted radionuclide therapy (radium-223\/strontium-89) versus conventional percutaneous vertebroplasty (PVP) combined with radionuclide therapy in the treatment of malignant tumor-related pathological vertebral fractures, and to evaluate differences between the two surgical approaches in postfracture pain relief, vertebral morphological reconstruction, spinal functional recovery, and quality-of-life improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A retrospective analysis was performed on 125 patients with pathologically confirmed malignant tumor bone metastasis-related pathological vertebral fractures treated between January 2022 and December 2024. All patients received targeted radionuclide therapy, and vertebroplasty was performed 14\u201321 d after the last radionuclide dose. Patients were divided into the curved vertebroplasty combined with radionuclide therapy group (study group,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 63) and the conventional PVP combined with radionuclide therapy group (control group,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 62). The primary outcome was the Visual Analogue Scale (VAS) pain score. Secondary outcomes included the postfracture vertebral height recovery rate, the Oswestry Disability Index (ODI), the Roland\u2013Morris Disability Questionnaire (RMDQ), bone cement distribution, vertebral kyphotic angle, and SF-36 quality-of-life score. Patients were followed for 6 months, and radionuclide therapy-related adverse events were monitored.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Baseline characteristics were comparable between the two groups (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &gt; 0.05). At 3 and 6 months after pathological fracture surgery, VAS scores were significantly lower in the study group than in the control group (1.6\u2009\u00b1\u20090.8 vs. 2.5 \u00b1\u20091.0; 1.4\u2009\u00b1\u20090.7 vs. 2.4\u2009\u00b1\u20090.9; both\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.01). At all postoperative time points, the study group demonstrated significantly superior vertebral height recovery rates, ODI, and RMDQ improvement (all\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      s &lt; 0.017), as well as a better kyphotic angle correction (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.017). The anterior\u2013middle column bone cement fill rate was significantly higher in the study group (88.4%\u2009\u00b1\u20099.1% vs. 74.6%\u2009\u00b1\u200913.2%,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001), with no intraspinal cement leakage. All eight SF-36 domain scores were significantly higher in the study group at 6 months (all\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      s &lt; 0.001). Hematological toxicity rates did not differ significantly between groups (14.3% vs. 12.9%,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.819).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In the surgical management of malignant tumor-related pathological vertebral fractures, the curved vertebroplasty system combined with targeted radionuclide therapy demonstrates significantly superior postfracture pain control, vertebral morphological reconstruction, spinal functional recovery, and quality-of-life improvement compared with conventional PVP combined with radionuclide therapy, without increasing radionuclide-related toxicity. The precise anterior\u2013middle column cement filling achieved by the curved system, combined with the systemic antitumor effect of radionuclide therapy, establishes a synergistic precision treatment model of local surgical reconstruction plus systemic radionuclide therapy for tumor-related pathological vertebral fractures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10849785261461404","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:18:16Z","timestamp":1782281896000},"source":"Crossref","is-referenced-by-count":0,"title":["Curved Vertebroplasty System Combined with Targeted Radionuclide Therapy for Tumor-Related Pathological Vertebral Fractures"],"prefix":"10.1177","author":[{"given":"Haitao","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Orthopedics, Beijing Long Fu Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Huai\u2019an Clinical Medical College of Jiangsu University (Huai\u2019an Hospital of Huai\u2019an City), Huai\u2019an City, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7666-2709","authenticated-orcid":false,"given":"Zhengxin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00216-3"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.7219"},{"issue":"11","key":"e_1_3_2_4_1","first-page":"E658","article-title":"Predictors of survival in patients with symptomatic spinal bone metastases: A systematic review","volume":"41","author":"Bollen L","year":"2016","unstructured":"3.Bollen L, , Wibmer C, , Van der Linden YM, et al. Predictors of survival in patients with symptomatic spinal bone metastases: A systematic review. Spine (Phila Pa 1976) 2016;41(11):E658\u2013E665.","journal-title":"Spine (Phila Pa 1976)"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2005.03.003"},{"issue":"1","key":"e_1_3_2_7_1","first-page":"71","article-title":"The effect of radiation therapy on the incidence of spinal fractures in patients with bone metastases","volume":"190","author":"Rief H","year":"2014","unstructured":"6.Rief H, , Petersen LC, , Omlor G, et al. The effect of radiation therapy on the incidence of spinal fractures in patients with bone metastases. Strahlenther Onkol 2014;190(1):71\u201376.","journal-title":"Strahlenther Onkol"},{"issue":"4","key":"e_1_3_2_8_1","first-page":"E339","article-title":"Unique characteristics and challenges of percutaneous vertebroplasty in treating pathological vertebral compression fractures caused by malignant tumors","volume":"23","author":"Chen B","year":"2020","unstructured":"7.Chen B, , Li Y, , Yang X, et al. Unique characteristics and challenges of percutaneous vertebroplasty in treating pathological vertebral compression fractures caused by malignant tumors. Pain Physician 2020;23(4):E339\u2013E350.","journal-title":"Pain Physician"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-024-07951-8"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/os.13800"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2023.10.035"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0000000000000048"},{"issue":"4","key":"e_1_3_2_13_1","first-page":"e222535","article-title":"Vertebroplasty versus Active Control Intervention for Chronic Vertebral Compression Fractures: The VERTOS V RCT","volume":"307","author":"Firanescu CE","year":"2023","unstructured":"12.Firanescu CE, , de Vries J, , Lodder P, et al. Vertebroplasty versus Active Control Intervention for Chronic Vertebral Compression Fractures: The VERTOS V RCT. Radiology 2023;307(4):e222535.","journal-title":"Radiology"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-023-03719-3"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-024-07689-3"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.067"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000273"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-36905-8"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S456093"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"issue":"8","key":"e_1_3_2_21_1","first-page":"2226","article-title":"Joint EANM\/SNMMI\/IAEA guidelines for theranostics in oncology","volume":"51","author":"Herrmann K","year":"2024","unstructured":"20.Herrmann K, , Giovanella L, , Santos AO, et al. Joint EANM\/SNMMI\/IAEA guidelines for theranostics in oncology. Eur J Nucl Med Mol Imaging 2024;51(8):2226\u20132257.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10849785261461404","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10849785261461404","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10849785261461404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T19:49:24Z","timestamp":1782503364000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10849785261461404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":20,"alternative-id":["10.1177\/10849785261461404"],"URL":"https:\/\/doi.org\/10.1177\/10849785261461404","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"10849785261461404"}}